Title:

Analysis of presence and short-term persistence of SARS-CoV-2 neutralizing antibodies in COVID-19 convalescent plasma donors.

Authors:

*Kyle Annen, D.O.¹

*Thomas E. Morrison, Ph.D.²

Melkon G. DomBourian, M.D.¹

Mary K. McCarthy, Ph.D.²

Leah Huey, B.S.³

Patricia Merkel, M.S.³

Gillian Andersen, M.S., MT(ASCP)¹

Eileen Schwartz, RN1

Vijaya Knight, M.D., Ph.D.^{3, #}

*Co-first authors

¹Department of Pathology and Laboratory Medicine, University of Colorado School of Medicine and Children's Hospital, Colorado

² Department of Immunology and Microbiology, University of Colorado School of Medicine

³ Department of Pediatrics, Section of Allergy and Immunology, University of Colorado School of Medicine and Children's Hospital, Colorado.

Corresponding author

Key Words: COVID-19, SARS-COV-2, convalescent plasma, neutralizing antibody

Abstract

1

In March 2020, the FDA approved the use of COVID-19 convalescent plasma (CCP) as 2 an investigational new drug for treatment of COVID-19. Since then, collection of CCP 3 from COVID-19 recovered patients has been implemented in several donor centers 4 across the country. Children's Hospital Colorado rapidly put into practice a CCP 5 6 collection protocol, necessitating the development and implementation of assays to evaluate SARS-CoV-2 antibodies in CCP units. We evaluated 87 separate units of CCP 7 8 collected from 36 donors over two to four sequential donations using both antigen-9 binding assays for SARS-CoV-2 nucleoprotein and spike antigens, and a live virus focus reduction neutralization test (FRNT50). Our data shows that the majority of 10 donors (83%) had a FRNT50 titer of 1:80 or greater, and 61% had a titer ≥ 1:160, which 11 meet the FDA's criteria for acceptable CCP units. Additionally, our data indicates that 12 analysis of antibodies to a single SARS-CoV-2 antigen is likely to miss a percentage of 13 14 seroconverters; however, these individuals tend to have neutralizing antibody titers of <1:80. Of note, there was considerable variability in the short term, sustained antibody 15 response, measured by neutralizing antibody titers, among our donor population. 16

Introduction

17

The Food and Drug Administration (FDA) authorized the use of COVID-19 convalescent 18 plasma (CCP) as an investigational new drug for the treatment of COVID-19 (1). 19 Initially, convalescent plasma donors were accepted only with a confirmed SARS-CoV-2 20 positive PCR. Donors were required to be symptom-free for at least 14 days prior to 21 22 donation, SARS-CoV-2 PCR negative upon subsequent testing, and meet all other blood donation eligibility requirements (2). The most recent guidance dropped the 23 24 requirement for a negative diagnostic test to qualify donors and describes an additional pathway for CCP donors to be deemed eligible to donate: a confirmed positive SARS-25 CoV-2-specific IgG based serology test (1). 26 During the early stages of the COVID-19 crises in the U.S., Children's Hospital of 27 Colorado (CHCO) rapidly developed and implemented protocols for the collection of 28 CCP. Since our first collection on March 31, 2020, we have collected 548 CCP units. 29 During the beginning phase of CCP collection, a primary challenge was identifying 30 donors who met the SARS-CoV-2 PCR positive test and symptom resolution criteria 31 (i.e., asymptomatic for 14 days or more). Although the FDA previously established that 32 33 plasma for the purpose of transfusion be collected no more frequently than every 28 days (3), the FDA has allowed for more frequent blood collection at the discretion of the 34 35 donation center medical director (personal correspondence Peter Marks, April 16, 36 2020). This exception could significantly improve access to CCP by allowing for an earlier return of donors who had previously been successfully screened and tested. 37 Since coagulation factors, such as fibringen and albumin, are expected to be replaced 38 39 in a donor's plasma within one week(4), several donation centers in the country,

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

including CHCO, allowed repeat convalescent plasma donors as frequently as every 7 days. However, the impact on the donors anti-SARS-CoV-2 antibody levels with this frequency of donation, or any frequency, is unknown, as is the pattern of decline or retention of antibodies to SARS-CoV-2. A number of assays for detection of SARS-CoV-2 antibodies, including ELISA, high throughput immunoassay platforms, and rapid detection lateral flow assays became available in late March, enabling relatively rapid screening of CCP units for the presence of anti-SARS-CoV-2 antibodies, commonly to either the SARS-CoV-2 nucleocapsid or spike antigens, such as the S1 and receptor binding domain (RBD) of the spike protein (5, 6). However, FDA recommendations state that CCP units that are eligible for transfusion into COVID-19 patients should have a neutralizing antibody titer of at least 1:80, and preferably 1:160 (2). This guidance poses challenges for laboratories that are screening CCP units for SARS-CoV-2 antibodies with antigen binding assays, many of which are primarily qualitative in nature, and do not provide information regarding potential for SARS-CoV-2 neutralization. Therefore, a comparison of antigen binding assays with virus neutralizing antibody titer is increasingly important to enable triage of CCP units and to develop criteria for units that are suitable for transfusion into patients with COVID-19. Here, we compare two ELISA assays, both currently implemented in clinical laboratories for clinical diagnostics and for screening of CCP, with a SARS-CoV-2 virus neutralization assay in our CCP donor population. As CCP donors are currently permitted to return for relatively frequent plasma donations, we have additionally examined the persistence of SARS-CoV-2 antibodies using the neutralizing antibody

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

assay. These data contribute to our understanding of the neutralizing antibody response to SARS-CoV-2, its correlation with development of N and S1 binding antibodies, persistence of the neutralizing antibody response, and ultimately strengthen the criteria for CCP donors and analysis of CCP as a therapeutic for COVID-19. **Materials and Methods** COVID-19 convalescent plasma donors. SARS-CoV-2 PCR positive individuals who were eligible to donate plasma according to FDA criteria for CCP donors were enrolled under the CHCO CCP donor program. Aliquots of plasma and serum were stored at -80°C until analysis. SARS-CoV-2 IgG ELISA. Two commercial ELISAs, CE-marked Epitope Diagnostics Inc. (EDI, San Diego, CA) and Euroimmun (both CE-marked and FDA EUA approved, Lubeck, Germany) were utilized in this study. Both of the ELISAs report results qualitatively, based on a single dilution. The EDI ELISA utilizes a SARS-CoV-2 recombinant nucleocapsid (N) protein as the coating antigen. Positive and negative assay controls and samples were diluted 1:100 with the kit-specific COVID-19 IgG sample diluent and added to the wells, followed by a 30 min incubation at room temperature. Plates were washed five times using the kit-specific wash buffer and antihuman IgG horse radish peroxidase (HRP)-conjugated detection antibody was added, followed by a 30 min incubation. Plates were washed five times, and the signal was developed using tetramethylbenzidine (TMB). Absorbance was read at 450 nm within 10 min of halting the reaction.

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

The Euroimmun ELISA assay utilizes the S1 domain, which includes the receptor binding domain (RBD) of the SARS-CoV-2 spike protein (7). For this assay, a kitspecific calibrator, positive and negative controls and samples, were diluted 1:101 with the kit-specific dilution buffer and added to pre-coated wells. Following a 1 h incubation at 37°C, plates were washed three times with kit-specific wash buffer. Anti-human IgG-HRP conjugated detection antibody was added and plates were incubated for 30 min at 37°C followed by three washes. TMB was added and absorbance read at 450 nm within 10 min of halting the reaction. Interpretation of ELISA results. EDI ELISA: Positive, negative and borderline results were calculated based on the average optical density (OD) value for the negative control assayed in triplicate for the specific assay. The positive and negative cut-off values were calculated using the formula: positive cut-off = $1.1 \times (xNC+0.18)$ and negative cut-off = $0.9 \times (xNC+0.18)$, where xNC is the average OD₄₅₀ of triplicate negative control OD₄₅₀ values. Samples that had OD values between positive and negative cut-off values were reported as borderline. Euroimmun ELISA: The ratio of the sample OD₄₅₀ values to the calibrator OD₄₅₀ values was calculated for all samples and controls. Samples with a ratio of less than 0.8 were reported as negative, samples with a ratio of greater than 1.1 were reported as positive, and ratios between 0.8 and 1.1 were reported as borderline. Focus Reduction Neutralization Assay (FRNT). Vero E6 cells (ATCC, Manassas, VA) were seeded in 96-well plates. Serum samples were heat inactivated and serially diluted (2-fold, starting at 1:10) in DMEM (ThermoFisher, Pittsburgh, PA, USA) plus 1% FBS

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

(manufacturer, city, state) in 96-well plates. Approximately 100 focus-forming units (FFU) of SARS-CoV-2 USA-WA1/2020 (8)(deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH) was added to each well and the serum plus virus mixture was incubated for 1 h at 37°C. At the end of 1 h, medium was removed from cells and the serum sample plus virus mixture was added for 1 h at 37°C. After 1 h, samples were removed and cells overlaid with 1% methylcellulose (MilliporeSigma, St. Louis, MO) in MEM (ThermoFisher, Pittsburgh, PA, USA)/2% FBS and incubated 30 h at 37°C. Cells were fixed with 4% paraformaldehyde (Acros Organics, Pittsburgh, PA, USA) and probed with 1 µg/mL of an anti-SARS-CoV spike monoclonal antibody (CR3022, Absolute Antibody, Boston, MA, USA) in Perm. Wash (1X PBS/0.1% saponin/0.1% bovine serum albumin [BSA]) for 2 h at RT. After washing, cells were incubated with horseradish peroxidase (HRP)-conjugated goat antihuman IgG (Southern Biotech, Birmingham, AL, USA, 1:1,000) for 1.5 h at RT. After washing, SARS-CoV-2-positive foci were visualized with TrueBlue substrate (ThermoFisher, Pittsburgh, PA, USA) and counted using a CTL Biospot analyzer and Biospot software (Cellular Technology Ltd, Shaker Heights, OH, USA). The FRNT₅₀ titer was calculated relative to a virus only control (no serum) set at 100%, using GraphPad Prism 8 (La Jolla, CA, USA) default nonlinear curve fit constrained between 0 and 100%. Data analysis: Data were analyzed using GraphPad Prism Version 8 (San Diego, CA) and Microsoft Excel 2016 (Microsoft, Redmond, WA). For OD₄₅₀ values and S1-RBD ratios, the mean and 95% confidence intervals were calculated using GraphPad Prism's statistical analysis package. Significant differences between groups were calculated

using Welch's test for unequal variances. The difference between groups was considered statistically significant when p<0.05.

Results

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

Characterization of donor serum samples. Eighty-seven samples from thirty-six CCP donors from the CHCO Blood Donor Center were included in this study. All plasma donors made an initial donation 12-42 days following a positive SARS-CoV-2 PCR result, and again at the intervals shown in Table 1. Of the thirty-six donors, twenty-four donated plasma twice, nine donors, three times, and three donors, four times. The intervals between sequential plasma donations ranged from 7 to 24 days. Comparison of N and S1-RBD antibody detection with virus neutralizing activity. To determine if qualitative IgG antibody detection by ELISA, whether against the N or the S1-RBD antigen, correlated with virus neutralizing activity, samples were analyzed for the presence of anti-N IgG antibodies using the Epitope Diagnostics ELISA, anti-S1-RBD IgG antibodies using the Euroimmun ELISA, and neutralizing activity using a live virus focus reduction assay. Samples with a neutralizing antibody titer of 1:80 or greater had a positive or borderline-positive result for both N and S1-RBD IgG antibodies, with the exception of sample 018-D (neutralizing titer of 1:85), which was positive for N and negative for S1-RBD, and sample 023-D (neutralizing titer of 1:91) which was negative for N and was not analyzed for S1-RBD antibodies (Table 2). More variability between anti-N and anti-S1-RBD IgG ELISA results was noted for samples with lower neutralizing antibody titers, particularly for the five samples that had neutralizing titers of <1:40. These samples were negative for anti-N IgG antibodies; four of the five samples

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

were either negative or borderline-positive for anti-S1-RBD IgG, and one was positive. Of note, donor 019-D (samples 1 and 2) remained persistently negative for anti-N lgG, had a marginal increase in anti-S1-RBD IgG on the second CCP donation, and had very low FRNT50 titers. To determine whether OD₄₅₀ values for anti-N IgG antibodies or the ratio for anti-S1-RBD IgG antibodies was predictive of neutralizing antibody titers, we compared the numerical values associated with a positive or negative ELISA result with the corresponding neutralizing antibody titer (Figure 1). Samples with a neutralizing antibody titer of <1:80 had the lowest OD₄₅₀ values for N or ratios for S1-RBD. An increase in OD₄₅₀ value or an increase in S1-RBD ratio independently correlated with a significant increase in neutralizing antibody titers (Figures 1A and 1B). However, given the wide variability among OD₄₅₀ values and ratios within each group, we performed a 3way comparison of the data to examine whether there was a relationship between the level of positivity for anti-N IgG, anti-S1-RBD IgG, and neutralizing antibody titers (Figure 2). Two of the samples with the highest neutralizing antibody titers, both from donor 001-D, had the highest ratios for anti-S1-RBD IgG, and although they were strongly positive for anti-N IgG antibodies, they did not have the highest OD₄₅₀ values in this sample set. In general, samples with both low anti-N IgG and anti-S1-RBD IgG numerical values correlated well with low or minimal neutralizing activity. Five samples with neutralizing titers between 1:1,000-1:1,500 had varying levels of positivity for anti-N IgG and anti-S1-RBD IgG, and three samples with the highest OD₄₅₀ values for anti-N IgG antibodies had neutralizing antibody titers in the range of 1:200 (Figure 2).

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

Given that these ELISAs were performed using a single dilution of serum, it is possible that the numerical values obtained are not in the linear range, and, therefore, these results affect correlations with neutralizing antibody titers as the FRNT50 is a quantitative assay. Nevertheless, an anti-N IgG OD₄₅₀ of 0.4 and above correlated well with a neutralizing titer of ≥1:80 in 90% of the samples, and an anti-S1-RBD IgG ratio of 3.0 and above correlated with ≥1:80 neutralizing antibody titer in 82% of the samples (Table 3 and Figure 2). Only three samples with a neutralizing titer of ≥1:80 had an anti-N IgG OD₄₅₀ <0.4 and an anti-S1-RBD IgG ratio <3.0. In general, when the anti-N IgG OD₄₅₀ value was <0.4, the anti-S1-RBD IgG ratio was >3.0 and vice versa, indicating that a combination of the two assays accurately captured 96% of CCP samples with ≥1:80 neutralizing activity. Additionally, specificity of the anti-S1-RBD IgG ratio was greater for neutralizing titers, as 93% of samples with <1:80 neutralizing activity had <3.0 anti-S1-RBD IgG ratios, whereas greater than a quarter (27%) of these samples had anti-N IgG OD₄₅₀ values of >0.4 (Table 3). As recommended by the FDA, CCP units eligible for the rapeutic use for COVID-19 patients are expected to have a neutralizing antibody titer of at least 1:80 and preferably ≥1:160. Of the 87 samples tested in this study, 72/87 (82.7%) had a neutralizing titer of ≥1:80 and 53/87 (60.9%) had a titer of ≥1:160 (Table 2 and Figure 3A). Neutralizing antibody titers were, in general, between 1/80 and 1/500 for the majority of samples tested (52%). Approximately 20% had titers greater than 1/500 and very few (7 of the 87 tested) had neutralizing antibody titers of >1:1000 (Figure 3A). Sustainability of the antibody response. Because analysis of N and S1-RBD IgG antibodies by single dilution ELISA is qualitative at best, we chose to analyze the

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

robustness and sustainability of the SARS-CoV-2 antibody response by analyzing neutralizing antibody titers in sequential samples from the 36 donors included in this study. Neutralizing antibody titers at the time of initial donation varied significantly from <1:10 to almost 1:2000 (Figure 3B). Aggregate analysis of plasma samples at the time of initial donation, or between seven and 24 days following initial collection, showed an increase from baseline at the time of the second donation and an average greater increase at the third donation; however, these increases were not statistically significant (Figure 3B). Although the mean neutralizing antibody titer appeared to decrease at the time of the fourth donation, there were too few samples to ensure statistical significance at this time point. Given that the considerable variability of SARS-CoV-2 neutralizing antibody titers between donors may also be confounded by the interval between donations and the initial neutralizing antibody titer, we analyzed longevity of neutralizing antibody responses for individual donors. The majority of individuals donated two plasma units 7-24 days apart (Figures 4A and B). Only one donor (001-D) had a baseline titer of >1/1500, which rose to >1/2000 at the time of the second donation (Figure 4A). Of the 24 donors who donated plasma twice, neutralizing antibody titers decreased in seven (Figure 4B), increased slightly (< 2-fold) or remained relatively unchanged in 12, and increased between 2-6-fold in five donors (Figure 4C). Of the 12 donors with three or four sequential donations (Figures 5A and B), antibody titers increased or remained relatively unchanged from the initial plasma donation for seven donors and declined in the remaining five. Donor 015-D had the greatest decline in titers, from a 5-fold increase at the second and third donation to a 2-fold increase over baseline at the fourth donation. In general, for the seven donors who had an increase in

neutralizing antibody titer over time, the fold increase in titer was moderate, with the exception of donor 013-D who had a 12-fold increase (from 1/90 to 1/1122). Overall, 24/36 (67%) and 12/36 (33%) donors had either sustained or declined neutralizing antibody titers, respectively, during the observation period compared with their individual baseline titers.

Discussion

Passive transfer of convalescent plasma has been utilized to combat infection with a variety of pathogens including the 1918 H1N1 influenza virus (9), the 2009 H1N1 influenza virus (10), and the SARS-CoV-2 -related coronaviruses, MERS and SARS-CoV (11, 12). Transfer of CCP for the treatment of COVID-19 received FDA approval for use as an investigational therapeutic in March of 2020 (13). Data regarding its efficacy continues to accumulate, and some initial successes have been reported (14-19). We have collected 548 units at CHCO to date. As this program ramps up to meet the growing need for CCP to combat the COVID-19 crisis, there is a need to screen these units as quickly and as accurately as possible for titer and quality of SARS-CoV-2 antibodies.

A large variety of serological assays for analysis of SARS-CoV-2 antibodies targeting the immunodominant nucleocapsid and spike antigens are now available with varying levels of regulatory approval and validation. However, these antigen binding assays do not provide information on neutralizing capacity of SARS-CoV-2 antibodies. Given that the FDA's recommendation for CCP is a neutralizing antibody titer of at least 1:80 and

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

preferably 1:160, and that neutralizing antibody assays cannot be easily implemented in most clinical laboratories, it is important to evaluate correlations between antigen binding assays and neutralizing antibody titers in order to triage CCP units and enable selection of units that are likely to have recommended neutralizing titers. An analysis of 159 serum samples from healthy, COVID-19 recovered individuals revealed that while samples with high IgG ELISA titers to the RBD antigen generally correlated with neutralizing activity as determined by a PRNT assay, only half of the individuals tested had >1:160 PRNT50 titer (20). Our comparison of anti-N IgG antibodies, measured by the EDI assay, and anti-S1-RBD IgG antibodies, measured by the Euroimmun assay, indicates that an increase in the relative level of positivity of either antibody correlated with an increase in neutralization titer, however, these correlations were mutually exclusive. The level of positivity for S1-RBD antibodies had a higher correlation with neutralizing activity, as would be expected, since viral entry is mediated by the spike protein and anti-N antibodies are non-neutralizing (21, 22). SARS-CoV-2 N antigen is highly antigenic (23), and while some of the donor samples were highly positive for anti-N IgG antibodies, they did not have corresponding high neutralizing antibody titers. The drawback of these qualitative assays is that they are based on a single dilution and, therefore, may not measure antibodies in the linear range. Despite this, our data indicate that samples with an anti-N IgG OD₄₅₀ of 0.4 by the EDI assay, or a ratio of 3.0 for measurement of anti-S1-RBD IgG antibodies by the Euroimmun assay accurately captured the majority of samples with neutralizing titers of ≥1:80. Furthermore, our data suggest that analysis of antibodies to a single SARS-CoV-2 antigen may not be sufficient to be predictive of neutralizing capability.

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

There is limited information about the peak and decline of SARS-CoV-2 antibodies following generation of an antibody response. In a scientific brief released by the World Health Organization (WHO), it was stated that there is "currently no evidence that people who have recovered from COVID-19 and have antibodies are protected from a second infection" and further stated that laboratory tests that detect antibodies to SARS-CoV-2, including rapid immunodiagnostic tests, need further validation to determine accuracy and reliability (24). The presence of antibodies and how long they last in an individual may be a critical factor as the economy continues to reopen and people who are considered immune may be deemed safe to return to work or other activities (WHO). In this context, antigen binding assays that have been implemented for rapid screening do not provide information regarding the functionality of these antibodies. Such information is typically generated from biological assays such as the FRNT50, described in our study, that examines the ability of CCP to neutralize viral replication in permissive cell lines. We found that close to 80% of the population of donor samples we tested had a neutralizing antibody titer of ≥1:80, and 60% ≥1:160, both of which meet the FDA's criteria for eligible CCP units. The longevity of the antibody response is a critical part of potential protection against reinfection, although such information continues to be gathered. Analysis of the longevity of the antibody response to SARS1 indicates that anti-SARS1 antibodies were detectable two to three years following infection in one study (25), and, in a second study, detectable for close to a year following infection but declined over the course of this observation period (26). Short term studies on the durability of the SARS-CoV-2

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

antibody response have provided variable results, and in particular seem to correlate with the severity of illness (27) while other reports suggest antibody titers may quickly wane, and concerns for reinfection, particularly with mild or no symptoms, are not unwarranted (28). For example, one reported case found that a SARS-CoV-2 confirmed infected patient's IgG antibodies became undetectable by day 80 (29). The significance of a waning antibody level may be particularly impactful when considering repeat collections from such donors, because of the effect that a waning antibody response may have on the amount and quality of the SARS-CoV-2 antibodies that are transfused as part of CCP therapy. As reported in the large study of 35,322 patients who received convalescent plasma as part of the Mayo Expanded Access Protocol, a higher antibody titer was correlated with reduced mortality (19). As a result, the recently issued Emergency Use Authorization from the FDA has established a cut-off value for a high antibody titer on the FDA approved Ortho VITROS SARS-CoV-2 IgG platform (30). Although the Signal-to-Cutoff ratio was provided for these reports, a correlation to neutralizing antibody titer thresholds in the prior FDA requirement of >1:80 titer with preference for ≥1:160 titer was not provided. This incites the question of the adequacy of the minimum threshold for CCP treatment and may impact future collections if the threshold is increased for the rapeutic efficacy. Our data suggests that a majority of donors (67%) had a neutralizing antibody response that was either sustained or increased over the short period of approximately three weeks to two months following a positive SARS-CoV-2 PCR result, and a smaller percentage (33%) showed a decrease in neutralizing antibody titer over sequential donations. Notably, repeat donations did not appear to affect antibody titer for the

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

majority (67%) of donors. A drawback of our dataset is that for the majority of donors, we were able to test only two time points (7-24 days apart) following a positive SARS-CoV-2 PCR test, making it challenging to comment on longer term sustainability of the response. The longevity of the SARS-CoV-2 antibody response and the level of protection it will provide for reinfection is yet to be determined. Authorship Contributions. KA and MD developed the CCP donor program and contributed to writing and critical review of the manuscript. TEM and MKM developed the FRNT50 assays and contributed to writing and data analysis, MKM performed the FRNT50 assays and FRNT50 data analysis, LH, PAM and GA performed the EDI and Euroimmun ELISAs, analyzed ELISA data and contributed to writing, VK conceptualized the manuscript, contributed to writing, data analysis and critical review of the manuscript. Disclosure of Conflicts of Interest. The authors report no conflicts of interest **Funding.** This study was funded by the Department of Pediatrics, the Department of Immunology and Microbiology, University of Colorado School of Medicine and Children's Hospital, Colorado.

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

Figure legends: Figure 1. Comparison of reciprocal FRNT50 titer with either anti-nucleocapsid IgG (A) or anti-S1-RBD IgG (B). Data are the mean and 95% confidence intervals for each group of FRNT50 titers. N=86 for FRNT50 vs anti-N antibodies and N=84 for FRNT50 vs anti-S1-RBD antibodies. *=p<0.05, **=p<0.001, and ***=p<0.0001 using Welch's test for unequal variance. Figure 2: Comparison of anti-nucleocapsid IgG (OD₄₅₀, x-axis), anti-S1-RBD IgG (ratio, v-axis), and FRNT50 reciprocal titer (relative size of bubble, larger bubbles correspond to higher titers). Eighty-five samples were compared for correlation among anti-N, anti-S1-RBD and neutralizing antibody titers. Two samples with the highest FRNT50 titers (red circles), also had the highest S1-RBD ratios and moderately high levels of anti-N1. Three samples with the highest anti-N OD₄₅₀ values had FRNT50 values of approximately 1:200 (purple circles), while five samples (green circles) had FRNT50 values of approximately 1:1000 but had varying levels of anti-N and anti-S1-RBD antibodies. Dashed lines indicate cut-off values for OD₄₅₀ and ratios above which 90% of FRNT50 values were 80 or greater. Figure 3. FRNT50 titers in CCP donors (A) and FRNT50 titers grouped by sequential CCP donations (B). Eighty-seven samples were analyzed for FRNT50 titers. Data are grouped by FRNT50 titer and the number of samples in each group is indicated (A). FRNT50 titers correlated with CCP collection time point. The difference between groups

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

was considered significant (p<0.05) using Welch's test for unequal variances. ns=not significant. Figure 4. Change in FRNT50 titers over two sequential donations. FRNT50 titer increased or remained relatively unchanged (A, n=17 donors). FRNT50 titers decreased from the initial to the second donation (B, n=7). Fold increase from initial donation for donors with two sequential donations (C, n=24). Figure 5. Change in FRNT50 titer over three or four sequential donations. (A) FRNT titers over the course of three or four donations for individual donors. (B) Fold-increase from initial donation. n=12. References 1. https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-ordevice-exemption-ide-process-cber/recommendations-investigational-covid-19convalescent-plasma. 2. https://www.fda.gov/media/136798/download. 3.https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=630.3. Ciszewski TS, Ralston S, Acteson D, Wasi S, Strong SJ. Protein levels and 4. plasmapheresis intensity. Transfus Med. 1993;3(1):59-65. 5. Kohmer N. Westhaus S. Ruhl C. Ciesek S. Rabenau HF. Clinical performance of different SARS-CoV-2 IgG antibody tests. J Med Virol. 2020.

- 6. Kruttgen A, Cornelissen CG, Dreher M, Hornef M, Imohl M, Kleines M.
- Comparison of four new commercial serologic assays for determination of SARS-CoV-2
- 383 IgG. J Clin Virol. 2020;128:104394.
- Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure,
- Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell.
- 386 2020;181(2):281-92 e6.
- 8. Harcourt J, Tamin A, Lu X, Kamili S, Sakthivel SK, Murray J, et al. Severe Acute
- 388 Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United
- 389 States. Emerg Infect Dis. 2020;26(6):1266-73.
- 390 9. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent
- 391 blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern
- 392 Med. 2006;145(8):599-609.
- 10. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, et al. Convalescent plasma
- treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009
- 395 virus infection. Clin Infect Dis. 2011;52(4):447-56.
- 396 11. Soo YO, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KK, et al. Retrospective
- comparison of convalescent plasma with continuing high-dose methylprednisolone
- treatment in SARS patients. Clin Microbiol Infect. 2004;10(7):676-8.
- 399 12. Ko JH, Seok H, Cho SY, Ha YE, Baek JY, Kim SH, et al. Challenges of
- 400 convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a
- single centre experience. Antivir Ther. 2018;23(7):617-22.
- 402 13. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-
- 403 <u>update-daily-roundup-march-24-2020</u>.

- 14. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent
- plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A.
- 406 2020;117(17):9490-6.
- 407 15. Salazar E, Perez KK, Ashraf M, Chen J, Castillo B, Christensen PA, et al.
- Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent
- 409 Plasma. Am J Pathol. 2020;190(8):1680-90.
- 410 16. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically III
- Patients With COVID-19 With Convalescent Plasma. JAMA. 2020.
- 412 17. Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, et al. Treatment with
- convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020.
- 414 18. Zeng QL, Yu ZJ, Gou JJ, Li GM, Ma SH, Zhang GF, et al. Effect of Convalescent
- Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease
- 416 2019. J Infect Dis. 2020;222(1):38-43.
- 19. Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, et al.
- 418 Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-
- 419 19: Initial Three-Month Experience. medRxiv. 2020.
- 420 20. Lee WT, Girardin RC, Dupuis AP, Kulas KE, Payne AF, Wong SJ, et al.
- Neutralizing Antibody Responses in COVID-19 Convalescent Sera. medRxiv.
- 422 2020:2020.07.10.20150557.
- 21. Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, et al. Structural basis of receptor
- recognition by SARS-CoV-2. Nature. 2020;581(7807):221-4.

- 425 22. Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, et
- al. Contributions of the structural proteins of severe acute respiratory syndrome
- coronavirus to protective immunity. Proc Natl Acad Sci U S A. 2004;101(26):9804-9.
- 428 23. Burbelo PD, Riedo FX, Morishima C, Rawlings S, Smith D, Das S, et al.
- Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe
- 430 Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019.
- 431 J Infect Dis. 2020;222(2):206-13.
- 432 24. https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-
- 433 context-of-covid-19.
- 434 25. Wu LP, Wang NC, Chang YH, Tian XY, Na DY, Zhang LY, et al. Duration of
- antibody responses after severe acute respiratory syndrome. Emerg Infect Dis.
- 436 2007;13(10):1562-4.
- 437 26. Woo PC, Lau SK, Wong BH, Chan KH, Chu CM, Tsoi HW, et al. Longitudinal
- 438 profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute
- respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with
- pneumonia due to the SARS coronavirus. Clin Diagn Lab Immunol. 2004;11(4):665-8.
- 441 27. Klein S, Pekosz A, Park HS, Ursin R, Shapiro J, Benner S, et al. Sex, age, and
- 442 hospitalization drive antibody responses in a COVID-19 convalescent plasma donor
- 443 population. medRxiv. 2020.
- 444 28. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA,
- et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N
- 446 Engl J Med. 2020.

Liu A, Wang W, Zhao X, Zhou X, Yang D, Lu M, et al. Disappearance of 29. antibodies to SARS-CoV-2 in a -COVID-19 patient after recovery. Clin Microbiol Infect. 2020. https://www.fda.gov/media/141477/download. 30.

Table 1. Interval (days) between CCP collection for individual donors.

Donor ID	Interval between positive PCR result	Interval between initial and second	Interval between second and third	Interval between third and fourth
	and initial donation	donation	donation	donation
001-D	33	7		
002-D	36	7	4=	
003-D	28	8	17	
005-D	29	7	9	
006-D	29	7	9	
007-D	42	8	6	8
008-D	20	19	•	_
009-D	18	12	8	7
010-D	33	18		
011-D	30	7	_	
012-D	19	13	7	
013-D	31	8	14	
014-D	25	13	11	_
015-D	22	11	7	7
016-D	36	8	9	
018-D	27	15		
019-D	26	8		
020-D	22	11	7	
021-D	32	8		
022-D	24	11		
023-D	31	8		
024-D	33	12		
025-D	29	12		
026-D	27	8		
027-D	26	20		
028-D	12	14		
029-D	36	5		
030-D	23	18		
031-D	28	11		
032-D	24	14		
033-D	22	24		
034-D	29	12		
035-D	36	9		
036-D	24	10		
037-D	26	9	13	

Table 2. Correlation of FRNT50 reciprocal titers and anti-N IgG or anti-S1-RBD IgG qualitative results.

	FRNT50	Anti- N	Anti-S1- RBD
1	10.00	Neg	Neg
2	13.90	Neg	Borderline
3	22.86	Neg	Neg
4	34.28	Neg	ND
5	35.1	Neg	Pos
6	39.08	Neg	Borderline
7	43.05	Neg	Borderline
8	43.2	Neg	Pos
9	44.16	Pos	Neg
10	45.81	Pos	Pos
11	48.75	Neg	Pos
12	64.1	Pos	Pos
13	66.07	Pos	Borderline
14	69.50	Pos	Pos
15	69.50	Pos	Pos
16	81.66	Pos	Pos
17	81.85	pos	Pos
18	85.11	Pos	Neg
19	85.31	Pos	Pos
20	85.5	Pos	Pos
21	90.57	Pos	Pos
22	90.99	Pos	Pos
23	91.41	Neg	ND
24	92.7	Pos	Pos
25	94.62	Pos	Pos

	•		•
	FRNT50	Anti-N	Anti-S1- RBD
26	100.93	Pos	Pos
27	103.75	pos	Pos
28	115.08	Pos	Pos
29	123.31	Pos	Pos
30	129.4	Pos	Pos
31	129.4	Pos	Pos
32	132.4	Pos	Pos
33	135.21	Pos	Pos
34	149.97	Pos	Pos
35	163.7	Pos	Pos
36	164.44	Pos	Pos
37	172.58	Borderline	Pos
38	179.06	Pos	Pos
39	180.72	Pos	Pos
40	198.15	Pos	Pos
41	200.45	Pos	Pos
42	204.2	Pos	Pos
43	206.54	Pos	Pos
44	217.27	Borderline	Pos
45	225.42	Pos	Pos
46	227.51	Pos	Pos
47	232.81	Pos	Pos
48	244.34	pos	Pos
49	248.9	Pos	Pos
50	254.10	Pos	Pos

	FRNT50	Anti-N	Anti-S1- RBD
51	257.63	Pos	Pos
52	260.02	Pos	Pos
53	263.63	Pos	Pos
54	307.61	Pos	Pos
55	309.74	Pos	Pos
56	314.8	Pos	Pos
57	317.69	Pos	Pos
58	327.34	Pos	Pos
59	338.06	Pos	Pos
60	361.41	Pos	Pos
61	363.08	Pos	Pos
62	372.39	Pos	Pos
63	375.84	Pos	Pos
64	439.54	Pos	Pos
65	451.86	Borderline	Pos
66	453.94	Pos	Pos
67	476.43	Pos	Pos
68	480.84	Pos	Pos
69	493.17	Pos	Pos
70	500.03	Pos	Pos
71	509.33	Pos	Pos
72	537.03	Pos	Pos
73	542.00	pos	Pos
74	559.76	Pos	Pos
75	574.12	Pos	Pos

	FRNT50	Anti- N	Anti-S1- RBD
76	628.06	Pos	Pos
77	717.79	Pos	Pos
78	722.77	Pos	Pos
79	744.73	Pos	Pos
80	820.4	Pos	Pos
81	1025.65	Pos	Pos
82	1047.13	Pos	Pos
83	1122.02	Pos	Pos
84	1177.61	Pos	Pos
85	1273.50	Pos	Pos
86	1936.42	Pos	Pos
87	2301.44	Pos	Pos

^{*}ND = not done.

Table 3: Correlation of >1:80 or <1:80 neutralizing antibody titers with anti-N or anti-S1-RBD level of positivity.

Neutralizing titer ≥1:80			
	Anti-S1-RBD IgG <3.0	Anti-S1-RBD IgG >3.0	Total anti-N IgG >0.4
Anti-N IgG <0.4	3 (4.2%)	4 (5.6%)	
Anti-N IgG > 0.4	10 (14.1%)	54 (76.1%)	90.2%
Total anti-S-RBD IgG > 3.0		81.7%	

	Neutralizing		
	Anti-S1-RBD IgG <3.0	Anti-S1-RBD IgG >3.0	Total anti-N IgG >0.4
Anti-N IgG <0.4	10 (71.4%)	0 (0%)	
Anti-N IgG > 0.4	3 (21.4%)	1 (7%)	28.4%
Total anti-S-RBD IgG > 3.0		7%	




Figure 1





Figure 2

A







Figure 3


В




Donor ID

30

Figure 4





31

Figure 5